Haichen Pharmaceutical disclosed its annual report on the evening of March 11. Haichen Pharmaceutical's revenue in 2017 was 455 million yuan, a year-on-year increase of 62%; net profit was 65.6 million yuan, up 45% year-on-year. Haichen Pharmaceutical intends to distribute a cash dividend of 2.50 yuan (including tax) to every 10 shares of all shareholders, and transfer 5 shares to every shareholder for every 10 shares.
Haichen Pharmaceutical released the first quarter of 2018 performance forecast on March 12. It is estimated that Haichen Pharmaceutical's net profit for the first three months of 2018 is 16.50 million yuan to 18.85 million yuan, compared with 7.785 million yuan in the same period of last year, an increase of 110%. ~140%.
Haichen Pharmaceutical said that the above predictions are based on the following reasons: 1. In the first quarter of 2018, Haichen Pharmaceutical promoted all work in an orderly manner according to the annual business plan, seized market opportunities, actively explored the market, and further expanded the sales scale. The operating results have increased steadily. 2. During the reporting period, Haichen Pharmaceutical expects the impact of non-recurring gains and losses on net profit to be approximately RMB 900,000, with less impact.
Founded in 2003, Nanjing Haichen Pharmaceutical Co., Ltd. is located in the national economic and technological development zone of Nanjing. It is a national high-tech enterprise integrating pharmaceutical R&D, production and marketing. The company has established national GMP standard freeze-dried powder injection, small-volume injection, cephalosporin needle, solid preparation and raw material medicine workshop. The product range covers cardiovascular, digestive, endocrine, anti-infective, and immune fields, and can produce more than 60 representative varieties. Launched torasemide for injection, cefotiam for injection, adenosine monophosphate for injection, ganciclovir sodium for injection, cefotaxime sodium for injection, tigecycline for injection, injection A number of clinically necessary products such as lansoprazole.
Various products of beard covers, providing product images and basic parameters with each beard covers and High Quality beard covers; We are a professional Chinese manufacturer of beard covers, and look forward to your cooperation!
Beard Guard,Beard Net,Beard Net,Disposable Non Woven Face Cover,anti falling beard cover, breathable beard cover
Jiangsu Asbao Medical Technology Co., Ltd. , https://www.iigloves.com